Target intelligence / Profile preview

Bordetella pertussis proteins (null)

Target
null
Molecular classification
Other (collection that may include:, Enzyme, Toxin, Adhesin, Transporter, Receptor (but not in conventional pharmacology), Autotransporter protein, Secreted factor
01

Overview

Bordetella pertussis proteins include a diverse array of molecules expressed by the bacterium Bordetella pertussis, a Gram-negative human pathogen responsible for whooping cough. Key proteins include Pertussis toxin (a major exotoxin and vaccine antigen, an AB5-type toxin involved in host immune modulation and cell injury), Filamentous hemagglutinin (a large surface adhesin responsible for attachment to respiratory tract epithelium), Pertactin (an outer membrane adhesin with a beta-helix structure important for host interaction), and fimbrial proteins (involved in adhesion and colonization). These proteins function collectively in immune evasion, adherence, toxin-mediated interference with host cell signaling, and have been used as vaccine antigens. However, the term "Bordetella pertussis proteins" should not be used to denote a specific molecular target; rather, individual proteins should be specified for research, therapeutic, or diagnostic purposes. "Bordetella pertussis proteins" is not a valid singular target; entries should refer to specific proteins such as "Pertussis toxin," "Filamentous hemagglutinin," "Pertactin," or "Serotype 2 fimbrial subunit". For structured data, specify the exact protein name required.

Other names
Bordetella pertussis virulence factorsB. pertussis proteinsBordetella proteins
02

Mechanism of action

Vaccine-induced immune responses; neutralization of toxins; blockade of adhesion to host cells

03

Biological functions

Immune evasionAdhesion to host cellsToxin-mediated disruption of host cell signalingIron acquisitionModulation of immune responseFacilitation of infection
04

Disease associations

Infection (Whooping cough/pertussis)
05

Safety considerations

Not applicable for the whole protein group. For specific proteins, concerns may include reactogenicity of vaccine antigens or failure of immune recognition due to antigenic variation.
06

Interacting drugs

DTP vaccines (Diphtheria, Tetanus, Pertussis)
07

Biomarkers

Serum antibody titers against Pertussis toxinAntibodies to filamentous hemagglutinin, pertactin, fimbriae

Beyond the preview

Go deeper on Bordetella pertussis proteins (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bordetella pertussis proteins (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call